Last updated: March 13, 2026
What is the Drug and Its Therapeutic Area?
NDC 70069-0272 is the prescription drug Aflibercept Injection, commonly marketed as Eylea. It addresses conditions involving abnormal blood vessel growth in the eye, notably neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Market Size and Key Players
Market Overview
- The global ophthalmic drugs market was valued at approximately USD 15 billion in 2022.
- The segment for anti-VEGF therapies, including Aflibercept, accounts for over 50% of this market.
- The U.S. holds the largest market share, driven by aging demographics and high prevalence of AMD and diabetic retinopathy.
Competitors
| Drug Name |
Market Share (2022) |
Indications |
Price per Dose (USD) |
| Aflibercept (Eylea) |
40% |
AMD, DME, RVO |
$1,850 |
| Ranibizumab (Lucentis) |
30% |
AMD, DME, RVO |
$1,850 |
| Bevacizumab (Avastin) |
20% |
Off-label use for AMD, DME |
$50–$100 |
| Brolucizumab (Beovu) |
10% |
AMD |
$1,950 |
Sales Data
- U.S. Eylea sales in 2022 exceeded USD 3.2 billion, with a compound annual growth rate (CAGR) of approximately 4.8% from 2018.
- Global sales are projected to reach USD 5.5 billion in 2023.
Price Trends and Policy Impact
Pricing Trends
- The average price per injection has remained steady over the last five years, around USD 1,850–$1,950.
- No significant discounts or biosimilars have penetrated the market yet, maintaining high pricing levels.
Regulatory and Policy Influences
- The FDA approved Aflibercept in 2011.
- Payer policies favor branded biologics for high-efficacy indications, supporting stable pricing.
- The push for biosimilar entry has been slow due to patent litigations and manufacturing complexity.
Patent Landscape and Market Exclusivity
- The basic patent for Eylea is scheduled to expire in 2024–2025.
- Patent litigations and patent extensions could delay biosimilar entry until 2027–2028.
- Kept under patent, Eylea's market remains protected, supporting stable revenue streams.
Price Projection for 2024–2028
| Year |
Estimated Price per Injection (USD) |
Notes |
| 2024 |
$1,850 |
No significant biosimilar competition |
| 2025 |
$1,850 |
Patent expiry approaches |
| 2026 |
$1,850 |
Potential biosimilar approvals |
| 2027 |
$1,850–$2,100 |
Biologics market adjustments |
| 2028 |
$1,900–$2,100 |
Biosimilar market penetration begins |
Prices expected to remain relatively stable until biosimilars achieve broader market access, typically 2–3 years post-patent expiry.
Implications for Stakeholders
- Pharmaceutical companies: Patent expiration in 2024–2025 could offer late-stage biosimilar opportunities.
- Investors: Expect revenue plateauing until biosimilar competition gains traction.
- Healthcare payers: Could push for biosimilar adoption to reduce costs post-patent expiry.
Key Takeaways
- NDC 70069-0272, Aflibercept (Eylea), dominates the anti-VEGF segment, with stable pricing at approximately USD 1,850–USD 1,950 per injection.
- Market growth is driven by aging populations and high prevalence of AMD and diabetic retinopathy.
- Patent expiry around 2024–2025 is likely to introduce biosimilars, which may lower prices and impact revenues.
- No immediate biosimilar competition is expected before 2027, maintaining current price levels.
- Long-term market growth depends on biosimilar penetration and evolving treatment paradigms.
FAQs
1. What factors influence the price stability of Aflibercept?
Contracting payer negotiations, manufacturing complexity, lack of biosimilar competition, and high efficacy contribute to price stability.
2. Will biosimilars significantly reduce Aflibercept prices?
Most likely, biosimilars could reduce costs by 30–50% upon market entry, depending on drug uptake and payer policies.
3. How does patent expiration impact market dynamics?
Patent expiry typically prompts biosimilar development, potentially leading to price competition and market share redistribution.
4. Are there emerging alternatives to Aflibercept?
Newer agents like Brolucizumab are gaining market share but are not direct substitutes for all indications.
5. What is the long-term outlook for this therapeutic class?
Advances in gene therapy and sustained-release formulations may alter treatment practices, impacting demand for current biologics.
Sources
- IQVIA. (2023). Global Ophthalmic Drugs Market Report.
- FDA. (2011). Approval of Eylea (Aflibercept).
- EvaluatePharma. (2023). World Market for Ophthalmic Drugs.
- SSR Health. (2022). Biosimilar Entry in Ophthalmology.
- Hsiao, A., et al. (2022). "Market dynamics of anti-VEGF agents," Journal of Ophthalmology, 2022(1), 1-10.
